Cannamedical

About Cannamedical

Cannamedical Pharma GmbH is an independent importer and distributor of medical cannabis products for the German and broader European markets. Founded in Cologne, Germany, by David Henn in November 2016, the company was established to capitalize on the legalization of medical cannabis for therapeutic use in Germany, which occurred the following year. Henn, who holds degrees in International Business and Financial Management and has prior experience in derivative trading at Deutsche Bank, founded the company to ensure patients have access to high-quality cannabis therapies. The company's business model is centered on the import, distribution, and wholesale of pharmaceutical-grade medical cannabis. Cannamedical sources its products from a network of more than 30 EU-GMP certified international producers in countries such as Portugal, Canada, and Australia, and distributes them to pharmacies and clinical facilities. As an independent entity not tied to any single producer, the company can offer a diverse portfolio of over 100 products, including various cannabis flower strains and extracts, ensuring a stable supply for patients. The business operates under strict pharmaceutical standards, holding a GDP (Good Distribution Practice) certification to complement its suppliers' GMP (Good Manufacturing Practice) standards, which guarantees quality control throughout the entire supply chain. A significant milestone was achieved in January 2019 when Cannamedical secured €15 million in a Series A funding round from Orkila Capital, which at the time was the largest equity investment in a European cannabis startup. Another key event occurred in September 2019, when the company imported the largest single shipment of medical cannabis into Germany from another EU country (Portugal). In 2021, Cannamedical merged with PS Pharma, a narcotics logistics provider, leading to the creation of the Semdor Pharma Group as the parent company, with Henn as its CEO. This strategic move enhanced its capabilities in logistics and distribution. Cannamedical continues to operate as an independent brand within the group, serving over 1,100 pharmacies and reaching more than 120,000 patients across Europe monthly.